Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23572880 | 0.99 | ADORA2A (0.37) | ADORA2ANPSR1KDM4EHTTHSD17B10 | |
| SCHEMBL19392172 | 0.80 | GRM5 (0.36) | KDM4EHTTHSD17B10 | |
| SCHEMBL21479937 | 0.76 | CTSK (0.33) | KDM4E | |
| SCHEMBL536588 | 0.73 | HTR1A (0.43) | ADORA2A | |
| SCHEMBL21479939 | 0.73 | ALDH1A1 (0.40) | KDM4EHSD17B10 | |
| SCHEMBL536693 | 0.70 | HTR1A (0.46) | ADORA2A | |
| SCHEMBL17115673 | 0.65 | NPSR1 (0.47) | NPSR1KDM4E | |
| SCHEMBL20202796 | 0.65 | NPSR1 (0.43) | NPSR1KDM4E | |
| SCHEMBL20416754 | 0.64 | P2RX7 (0.34) | ADORA2ANPSR1 | |
| SCHEMBL28857476 | 0.64 | CYP19A1 (0.41) | NPSR1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | disclosed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | disclosed |
| CN-112313234-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019196803-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEIGENE, LTD. (KY) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885NPSR1 150/4885KDM4E 3983/4885 |
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885NPSR1 150/4885KDM4E 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.